Mutations of KRAS and BRAF in chinese patients with colorectal carcinoma: Analyses of 966 cases

Chinese Journal of Pathology

Volumn 41, Issue 9, 2012, Pages 579-583

  Gao, Jing ^a   Sun, Zhi Uei ^a   Li, Yan Yan ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Colorectal neoplasms; DNA mutational analysis; Polymerase chain reaction; Sequence analysis

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CODON; COLON TUMOR; COLORECTAL TUMOR; EXON; FEMALE; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; RECTUM TUMOR; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CODON; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; EXONS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECTAL NEOPLASMS; SEX FACTORS; YOUNG ADULT;

EID: 84867495050     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2012.09.002     Document Type: Article

References (23)

1. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 2009, 360(14):1408-1417.
2. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the firstline treatment of metastatic colorectal cancer. J Clin Oncol, 2009, 27(5):663-671.
3. Liao W, Liao Y, Zhou JX, et al. Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. Anat Rec (Hoboken), 2010, 293(9):1506-1511.
4. Yokota T, Ura T, Shibata N, et al. BKAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer, 2011, 104(5):856-862.
5. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 2008, 26(35):5705-5712.
6. Borras E, Jurado I, Hernan I, et al. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer, 2011, 11:406.
7. Kwon MJ, Lee SE, Kang SY, et al. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers; comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathol Res Pract, 2011, 207(12):762-768.
8. Saridaki Z, Tzardi M, Papadaki C, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREC, EREC expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. PLoS One, 2011, 6(1):e15980.
9. Liou JM, Wu MS, Shun CT, et al. Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. Int J Colorectal Dis, 2011, 26(11):1387-1395.
10. Shen H, Yuan Y, Hu HC, et al. Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World J Castroenterol, 2011, 17(6):809-816.
11. Chang YS, Yeh KT, Chang TJ, et al. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer, 2009, 9:179.
12. Yunxia Z, Jun. C, Cuanshan Z, et al. Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer. BMC Med Genet, 2010, 11:34.
13. Li FH, Shen L, Li ZH, et al. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J Gastroenterol, 2010, 16(46):5881-5888.
14. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer, 2007, 97(8):1139-1145.
15. Sood A, McClain D, Maitra R, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KKAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer, 2012, 11(2):143-150.
16. Laurenl-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and ECFK status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol, 2009, 27(35):5924-5930.
17. Frenen H, De Schutter J, Jacobs H, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res, 2009, 15(9):3184-3188.
18. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res, 2009, 69(5):1851-1857.
19. Vasovcak P, Pavlikova K, Sedlacek Z, et al. Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients. PLoS One, 2011, 6(8):e24114.
20. Gao J, Wang TT, Yu JW, et al. Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients. Chin J Cancer Res, 2011, 23(4):271-275.
21. Pajkos G, Kiss I, Sundor J, et al. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res, 2000, 20(3A):1695-1701.
22. Mao C, Liao RY, Qiu IX, et al. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer; a meta-analysis. Mol Biol Rep, 2011, 38(4):2219-2223.
23. Zlobec I, Bihl MP, Schwarb H, et al. Clinicopathological and protein characterization of BRAF-and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer, 2010, 127(2):367-380.